Wanbury Limited – Investor Presentation Summary

Key Operational Highlights

  • 4X EBITDA scale-up between FY23-FY26 through de-bottlenecking projects & production scaleup
  • Capacity ramp-up in key existing API products: Metformin (25% increase in last 3 years) & Sertraline (20% increase in last 3 years)
  • 2 USFDA approved API facilities with 386 KL cumulative reactor capacity
  • 6 products in API portfolio, 100% chronic portfolio
  • Formulations business achieved financial break-even in FY26
  • 10+ active brands in Formulations portfolio with 300+ field force

Key drivers of operational performance: Efficient procurement practices, technical savings, de-bottlenecking projects, production scaleup

Segment-wise Performance

API Business: FY26 Revenue: ₹574 Crore | Focus on regulated markets (EU, Brazil, US) | 50%+ Gross contribution margins

Formulations Business: FY26 Revenue: ₹76 Crore | Focus on therapeutics including anti-cold & cough, anti-infective, anti-inflammatory, supplements | Operating through fully outsourced manufacturing model

Explanation of significant changes in segment performance: API business driven by significant global market share in key molecules; Formulations business rebuilding legacy brand portfolio

Financial Highlights

Revenue: ₹650.27 Crore (FY26)

EBITDA: ₹107.69 Crore (FY26)

PAT: ₹66.13 Crore (FY26)

EPS: ₹20.55 (FY26)

Margins: Gross Margin 57.6% (FY26), EBITDA Margin 16.6% (FY26), PAT Margin 10.2% (FY26)

YoY/QoQ comparison: Revenue up 8% YoY, EBITDA up 35% YoY, PAT up 117% YoY | Q4FY26 Revenue: ₹164.58 Crore (up 1% YoY, down 4% QoQ)

Drivers of financial performance: Improved plant utilisation, enhanced product yields, procurement efficiencies, reduction in finance costs

Key Risks: West Asia crisis impacting API export dispatches (mentioned as affecting Q4 performance)

Geographical Revenue Split

Domestic vs Export/Regional Revenue: 80%+ Export top line, with emphasis on developed markets

Balance Sheet Snapshot

Net Debt/Equity: Debt/EBITDA ratio of ~2X

Reserves: Other Equity: ₹109.51 Crore (FY26)

Current Assets/Liabilities: Current Assets: ₹238.56 Crore (FY26), Current Liabilities: ₹175.55 Crore (FY26)

Working Capital/Leverage Metrics: Trade Receivables: ₹143.27 Crore (FY26), Inventories: ₹50.63 Crore (FY26)

Financial Health Insights: 75% debt reduction from peak debt obligation of ~700 Crores, refinanced debt at lower interest rates

Capex & Cash Flow Health

Capital Expenditure: Modernised facilities with investment of ₹48 crore (FY25)

Free Cash Flow: Not Specified

Operating Cash Flow: ₹31.53 Crore (FY26)

Net Debt Movement: Long Term Borrowings: ₹147.15 Crore (FY26), Short Term Borrowings: ₹68.30 Crore (FY26)

Investment Rationale: Brownfield expansion, operational scale-up, borrowing cost optimization

Strategic & R&D Initiatives

Investments in Innovation: Upcoming 1.5 MW solar energy project at Satara | 4 new API molecule commercializations each year beginning FY27 | New therapeutic launches in Formulations (Paediatrics, Dermatology, Cardiology & Diabetes)

Expected impact on growth: Solar project to meet 70% of Patalganga site's energy requirements | New API molecules to drive growth in regulated markets

Strategic Rationale: Expanding into high-growth markets, reducing operational costs through backward integration, transitioning Formulations portfolio toward specialty and chronic segments

Industry Trends & Business Environment

Macro/Industry Trends: Developed market focus (EU, Brazil, US) for API business | Regulatory compliance requirements across global markets

Impact on Company: Emphasis on maintaining world-class EHS standards and regulatory approvals | Focus on sustainable energy solutions

Management Commentary & Growth Outlook

Strategic Outlook: "FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, de-bottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio." - Mr. Mohan Kumar Rayana, Promoter & Whole Time Director

FY Guidance: Target 4 commercial launches of new API molecules each year beginning FY27 | Formulations business to deliver sustainable profitability FY27 onwards

Market Share Targets: Aim double-digit market share for new API molecules | Significant global market share in existing products (Metformin ~30%, Sertraline ~30%, Tramadol ~11%)

Risks and Opportunities: West Asia crisis impacted Q4 API export dispatches | Strong pipeline of new molecules for future growth